Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Up 73,397.0% in March
by Renee Jackson · The Cerbat GemBioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 220,491 shares, an increase of 73,397.0% from the March 15th total of 300 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily volume of 1,093,413 shares, the days-to-cover ratio is currently 0.2 days.
Bioxytran Price Performance
Shares of Bioxytran stock traded down $0.00 on Friday, hitting $0.04. The company had a trading volume of 16,609 shares, compared to its average volume of 376,712. The firm has a market capitalization of $4.17 million, a P/E ratio of -1.23 and a beta of 2.50. Bioxytran has a twelve month low of $0.03 and a twelve month high of $0.20. The stock has a 50-day moving average of $0.04 and a 200-day moving average of $0.06.
About Bioxytran
Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.
Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.